Advertisement
Advertisement

TBPH

TBPH logo

Theravance Biopharma, Inc.

20.47
USD
Sponsored
+0.89
+4.57%
Feb 06, 15:59 UTC -5
Closed
exchange

After-Market

20.36

-0.11
-0.56%

TBPH Earnings Reports

Positive Surprise Ratio

TBPH beat 17 of 40 last estimates.

43%

Next Report

Date of Next Report
Mar 02, 2026
Estimate for Q4 25 (Revenue/ EPS)
$51.88M
/
$1.14
Implied change from Q3 25 (Revenue/ EPS)
+159.52%
/
+1528.57%
Implied change from Q4 24 (Revenue/ EPS)
+176.62%
/
-467.74%

Theravance Biopharma, Inc. earnings per share and revenue

On Nov 10, 2025, TBPH reported earnings of 0.07 USD per share (EPS) for Q3 25, beating the estimate of -0.13 USD, resulting in a 153.48% surprise. Revenue reached 19.99 million, compared to an expected 20.36 million, with a -1.81% difference. The market reacted with a +22.68% price change (close before vs. close after earnings).
Looking ahead to Q4 25, 9 analysts forecast an EPS of 1.14 USD, with revenue projected to reach 51.88 million USD, implying an increase of 1528.57% EPS, and increase of 159.52% in Revenue from the last quarter.

Industry Peers’ Earnings

Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.

logo
Takeda Pharmaceutical Company Limited - ADR
Report Date
Jan 30, 2026 For Q3 26
Estimate
$34.44
Actual
$65.64
Surprise
+90.61%
FAQ
For Q3 2025, Theravance Biopharma, Inc. reported EPS of $0.07, beating estimates by 153.48%, and revenue of $19.99M, -1.81% below expectations.
The stock price moved up 22.68%, changed from $15.08 before the earnings release to $18.50 the day after.
The next earning report is scheduled for Mar 02, 2026.
Based on 9 analysts, Theravance Biopharma, Inc. is expected to report EPS of $1.14 and revenue of $51.88M for Q4 2025.
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement